Aufbau und Einführung des neuen PLEURATUMOR-Registers der Deutschen Gesellschaft für Thoraxchirurgie: Eine erste Evaluation

Christian Werzmirzowsky
2017
Tumours of the pleura can be organized into primary and secondary forms. Primary degenerations derive from the pleura itself and are particularly attributable to airborne asbestos for MPMs. The usually benign pleural fibromas on the other hand are more likely of genetic origin. Secondary tumours originate in tissue other than the pleura. These carcinoses are mostly comprised of metastases of other primary tumours which spread into the pleura; thymomas in Masaoka-Koga stage IVa are also known
more » ... a are also known for pleural metastases. In order to collect data about these tumours, the thoracic surgeons in Regensburg developed the 'PLEURATUMOR-Register der DGT' in cooperation with DGAV's StuDoQ. The creation of this register comprised, amongst other things, the data of 56 thoracic departments from all over Germany. The finalised register has been online since January 1st 2015. The primary goal of this register is to record demographic, perioperative and follow-up data of patients diagnosed with pleural tumours who were treated surgically. The purposes of this collection of multicentre data are quality control on one hand and scientific research on the other. There are four tumour entities in this register: 1. Malignant pleural mesothelioma (MPM) 2. Thymoma / Thymic carcinoma with pleural diffusion (Masaoka-Koga stage IVa) 3. Pleural carcinoses 4. other (rare) primary pleural tumours During the first 15.5 months, 18 German thoracic clinics and departments participated in the creation of the register by contributing 156 usable cases. About 56% (n=88) of the entries were pleural carcinoses, 37% (n=57) MPMs, 4% (n=6) thymomas and 3% (n=5) other primary tumours of the pleura. Of these, 150 were initial tumours and 6 were recesses. For about 35% of patients, a potentially curative approach was documented. 53% of MPMs were treated curatively, 79% of pleural carcinoses palliatively with talc pleurodesis or durable pleural catheters. Furthermore, 20 HITHOC therapies were performed – mainly for MPMs (n=16). Despite the lack of indication for th [...]
doi:10.5283/epub.35698 fatcat:4yarlvjehjc53fzdcp2nb7yjju